PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
2435641-2	1986	Nafamostat inhibited trypsin, plasmin, thrombin, pancreatic kallikrein, Clr and Cls more potently than gabexate and leupeptin.	nafamostat	0-10	plasminogen	Homo sapiens	30-37
2739065-0	1989	[The effect of the protease inhibitor FUT-175 on phospholipase A2, complement, prostaglandins and prekallikrein during endotoxin shock].	nafamostat	38-45	phospholipase A2 group IB	Canis lupus familiaris	49-65
2739065-0	1989	[The effect of the protease inhibitor FUT-175 on phospholipase A2, complement, prostaglandins and prekallikrein during endotoxin shock].	nafamostat	38-45	kallikrein B1	Canis lupus familiaris	98-111
2435641-2	1986	Nafamostat inhibited trypsin, plasmin, thrombin, pancreatic kallikrein, Clr and Cls more potently than gabexate and leupeptin.	nafamostat	0-10	coagulation factor II, thrombin	Homo sapiens	39-47
2435641-8	1986	Unlike aprotinin and urinastatin, nafamostat and gabexate inhibited alpha 2-macroglobulin bound trypsin as well as free trypsin to the same extent.	nafamostat	34-44	alpha-2-macroglobulin	Homo sapiens	68-89
6086386-1	1984	The synthetic proteinase inhibitor, FUT-175 (6-amidino-2-naphthyl-4-guanidinobenzoate), strongly suppressed activation of Clr at 37 degrees C, causing 50% inhibition at 0.03 mM.	nafamostat	36-43	endogenous retrovirus group K member 25	Homo sapiens	14-24
6086386-1	1984	The synthetic proteinase inhibitor, FUT-175 (6-amidino-2-naphthyl-4-guanidinobenzoate), strongly suppressed activation of Clr at 37 degrees C, causing 50% inhibition at 0.03 mM.	nafamostat	45-85	endogenous retrovirus group K member 25	Homo sapiens	14-24
33996911-1	2021	Camostat, nafamostat, and bromhexine are inhibitors of the transmembrane serine protease TMPRSS2.	nafamostat	10-20	transmembrane serine protease 2	Homo sapiens	89-96
6618346-7	1983	On the other hand, the primary anti-DNP IgE antibody response to DNP-conjugated ovalbumin was slightly suppressed only by post-administration of FUT-175 in a dose of 100 mg/kg/day p.o.	nafamostat	145-152	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	80-89
6215361-1	1982	FUT-175 (6 amidino-2-naphthyl-4-guanidino benzoate-dimethanesulfonate), a new synthetic protease inhibitor, inhibits the enzyme activities of various proteases, such as Clr, C1 esterase, thrombin, kallikrein, plasmin and trypsin.	nafamostat	0-7	complement C1s	Rattus norvegicus	174-185
6215361-1	1982	FUT-175 (6 amidino-2-naphthyl-4-guanidino benzoate-dimethanesulfonate), a new synthetic protease inhibitor, inhibits the enzyme activities of various proteases, such as Clr, C1 esterase, thrombin, kallikrein, plasmin and trypsin.	nafamostat	0-7	coagulation factor II	Rattus norvegicus	187-195
6215361-1	1982	FUT-175 (6 amidino-2-naphthyl-4-guanidino benzoate-dimethanesulfonate), a new synthetic protease inhibitor, inhibits the enzyme activities of various proteases, such as Clr, C1 esterase, thrombin, kallikrein, plasmin and trypsin.	nafamostat	9-69	complement C1s	Rattus norvegicus	174-185
6215361-1	1982	FUT-175 (6 amidino-2-naphthyl-4-guanidino benzoate-dimethanesulfonate), a new synthetic protease inhibitor, inhibits the enzyme activities of various proteases, such as Clr, C1 esterase, thrombin, kallikrein, plasmin and trypsin.	nafamostat	9-69	coagulation factor II	Rattus norvegicus	187-195
33996911-3	2021	However, while camostat and nafamostat inhibit TMPRSS2 by forming a covalent adduct, the mode of action of bromhexine remains unclear.	nafamostat	28-38	transmembrane serine protease 2	Homo sapiens	47-54
33868970-10	2022	Among the drugs, the drug nafamostat may be more beneficial than the camostat in suppressing the activity of TMPRSS2.	nafamostat	26-36	transmembrane serine protease 2	Homo sapiens	109-116
32920751-0	2021	Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate.	nafamostat	73-92	fibrinogen beta chain	Homo sapiens	19-29
33821268-6	2021	The mechanism of the protease inhibitors nafamostat and camostat extend beyond inhibition of TMPRSS2 to coagulation-induced spike cleavage.	nafamostat	41-51	transmembrane serine protease 2	Homo sapiens	93-100
33821268-6	2021	The mechanism of the protease inhibitors nafamostat and camostat extend beyond inhibition of TMPRSS2 to coagulation-induced spike cleavage.	nafamostat	41-51	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	124-129
33791707-6	2021	In doing so, we demonstrate that serine protease inhibitors camostat, nafamostat, and gabexate inhibit through a covalent mechanism.	nafamostat	70-80	coagulation factor II, thrombin	Homo sapiens	33-48
33505639-2	2021	Recent studies showed that two drugs, Camostat and Nafamostat, might be repurposed to treat COVID-19 by inhibiting human TMPRSS2 required for proteolytic activation of viral spike (S) glycoprotein.	nafamostat	51-61	transmembrane serine protease 2	Homo sapiens	121-128
33671159-13	2021	First, administering of favipiravir to suppress SARS-CoV-2 and nafamostat to inhibit ACE2 function should be considered.	nafamostat	63-73	angiotensin converting enzyme 2	Homo sapiens	85-89
33382023-6	2020	Molecular docking score and MMGBSA Binding energy of Fisetin was better than Nafamostat, a known inhibitor of TMPRSS2.	nafamostat	77-87	transmembrane serine protease 2	Homo sapiens	110-117
33850886-2	2021	Neurotropin (NTP) has been used clinically to alleviate neuropathic pain, while nafamostat mesylate (NM) used clinical on pancreatitis patients through inhibiting synthetic serine protease.	nafamostat	80-99	coagulation factor II, thrombin	Homo sapiens	173-188
33157292-1	2021	Nafamostat, a serine proteinase inhibitor with various actions including antithrombin, antiplasmin, and antitrypsin effects, has been used in clinical practice to treat disseminated intravascular coagulation (DIC) and pancreatitis.	nafamostat	0-10	serpin family C member 1	Homo sapiens	73-85
31892740-0	2019	Nafamostat and sepimostat identified as novel neuroprotective agents via NR2B N-methyl-D-aspartate receptor antagonism using a rat retinal excitotoxicity model.	nafamostat	0-10	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	73-77
32824674-6	2020	Clinical studies on TMPRSS2 inhibitors, such as camostat, nafamostat, and bromhexine, are ongoing.	nafamostat	58-68	transmembrane serine protease 2	Homo sapiens	20-27
32532094-2	2020	We previously found that nafamostat mesylate, an existing drug used for disseminated intravascular coagulation (DIC), effectively blocked Middle East respiratory syndrome coronavirus (MERS-CoV) S protein-mediated cell fusion by targeting transmembrane serine protease 2 (TMPRSS2), and inhibited MERS-CoV infection of human lung epithelium-derived Calu-3 cells.	nafamostat	25-35	transmembrane serine protease 2	Homo sapiens	238-269
32532094-2	2020	We previously found that nafamostat mesylate, an existing drug used for disseminated intravascular coagulation (DIC), effectively blocked Middle East respiratory syndrome coronavirus (MERS-CoV) S protein-mediated cell fusion by targeting transmembrane serine protease 2 (TMPRSS2), and inhibited MERS-CoV infection of human lung epithelium-derived Calu-3 cells.	nafamostat	25-35	transmembrane serine protease 2	Homo sapiens	271-278
32532094-3	2020	Here we established a quantitative fusion assay dependent on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S protein, angiotensin I converting enzyme 2 (ACE2) and TMPRSS2, and found that nafamostat mesylate potently inhibited the fusion while camostat mesylate was about 10-fold less active.	nafamostat	202-221	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	110-111
32532094-3	2020	Here we established a quantitative fusion assay dependent on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S protein, angiotensin I converting enzyme 2 (ACE2) and TMPRSS2, and found that nafamostat mesylate potently inhibited the fusion while camostat mesylate was about 10-fold less active.	nafamostat	202-221	angiotensin converting enzyme 2	Homo sapiens	133-166
32532094-3	2020	Here we established a quantitative fusion assay dependent on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S protein, angiotensin I converting enzyme 2 (ACE2) and TMPRSS2, and found that nafamostat mesylate potently inhibited the fusion while camostat mesylate was about 10-fold less active.	nafamostat	202-221	angiotensin converting enzyme 2	Homo sapiens	168-172
32532094-3	2020	Here we established a quantitative fusion assay dependent on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S protein, angiotensin I converting enzyme 2 (ACE2) and TMPRSS2, and found that nafamostat mesylate potently inhibited the fusion while camostat mesylate was about 10-fold less active.	nafamostat	202-221	transmembrane serine protease 2	Homo sapiens	178-185
32532094-6	2020	Together, our study shows that nafamostat mesylate potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and also inhibits SARS-CoV-2 infection in vitro in a cell-type-dependent manner.	nafamostat	31-50	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	69-70
31892740-6	2019	The neuroprotective effects of nafamostat and the NR2B antagonist ifenprodil were remarkably suppressed by spermidine, a naturally occurring polyamine that modulates the NR2B subunit.	nafamostat	31-41	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	170-174
31892740-8	2019	Thus, nafamostat and sepimostat may exert neuroprotective effects against excitotoxic retinal degeneration through NMDA receptor antagonism at the ifenprodil-binding site of the NR2B subunit.	nafamostat	6-16	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	178-182
31449055-6	2019	They went on to evaluate the tryptase inhibitor nafamostat mesylate in a mouse model for severe DENV viremia.	nafamostat	48-67	tryptase alpha/beta 1	Mus musculus	29-37
31490455-8	2019	However, allopurinol, nafamostat, and octreotide showed similar efficacy as placebo in reducing the risk of PEP.	nafamostat	22-32	progestagen associated endometrial protein	Homo sapiens	108-111
31552177-0	2019	The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications.	nafamostat	64-83	serpin family A member 13, pseudogene	Homo sapiens	45-63
31552177-1	2019	Nafamostat mesylate (NM), a synthetic serine protease inhibitor first placed on the market by Japan Tobacco in 1986, has been approved to treat inflammatory-related diseases, such as pancreatitis.	nafamostat	0-19	serpin family A member 13, pseudogene	Homo sapiens	45-63
31552177-1	2019	Nafamostat mesylate (NM), a synthetic serine protease inhibitor first placed on the market by Japan Tobacco in 1986, has been approved to treat inflammatory-related diseases, such as pancreatitis.	nafamostat	21-23	serpin family A member 13, pseudogene	Homo sapiens	45-63
27550352-0	2016	Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay.	nafamostat	18-28	spike protein	Middle East respiratory syndrome-related coronavirus	99-108
30393114-0	2019	Identification of nafamostat mesilate as an inhibitor of the fat mass and obesity-associated protein (FTO) demethylase activity.	nafamostat	18-37	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	61-100
30393114-0	2019	Identification of nafamostat mesilate as an inhibitor of the fat mass and obesity-associated protein (FTO) demethylase activity.	nafamostat	18-37	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	102-105
30393114-0	2019	Identification of nafamostat mesilate as an inhibitor of the fat mass and obesity-associated protein (FTO) demethylase activity.	nafamostat	18-37	methyl-CpG binding domain protein 2	Homo sapiens	107-118
30393114-4	2019	A combination of thermodynamic and enzymatic activity studies provides an insight into the recognition of Nafamostat mesilate by FTO.	nafamostat	106-125	FTO alpha-ketoglutarate dependent dioxygenase	Homo sapiens	129-132
30193636-3	2018	The accuracy and reliability of the present method was demonstrated by measuring the IC50 value of two known fragments inhibiting thrombin, namely benzamidine and p-aminobenzamidine and a relatively weak inhibitor, nafamostat.	nafamostat	215-225	coagulation factor II, thrombin	Homo sapiens	130-138
30336548-3	2018	Nafamostat mesilate (FUT175), a synthetic serine protease inhibitor, enhances the chemosensitivity to cytotoxic agents in digestive system cancer cells by inhibiting NF-kappaB activation.	nafamostat	0-19	nuclear factor kappa B subunit 1	Homo sapiens	166-175
30336548-3	2018	Nafamostat mesilate (FUT175), a synthetic serine protease inhibitor, enhances the chemosensitivity to cytotoxic agents in digestive system cancer cells by inhibiting NF-kappaB activation.	nafamostat	21-27	nuclear factor kappa B subunit 1	Homo sapiens	166-175
30336548-5	2018	IR-induced upregulation of intranuclear NF-kappaB, FUT175 counteracted this effect.	nafamostat	51-57	nuclear factor kappa B subunit 1	Homo sapiens	40-49
30336548-8	2018	In addition, FUT175 prevented the migration and invasion of cancer cells caused by IR by downregulating the enzymatic activity of MMP-2/-9.	nafamostat	13-19	matrix metallopeptidase 2	Homo sapiens	130-138
30336548-9	2018	In conclusion, FUT175 enhances the anti-tumor effect of radiotherapy through downregulation of NF-kappaB and reduces IR-induced tumor invasiveness by directly inhibiting MMP-2/-9 in CRC cells.	nafamostat	15-21	nuclear factor kappa B subunit 1	Homo sapiens	95-104
30336548-9	2018	In conclusion, FUT175 enhances the anti-tumor effect of radiotherapy through downregulation of NF-kappaB and reduces IR-induced tumor invasiveness by directly inhibiting MMP-2/-9 in CRC cells.	nafamostat	15-21	matrix metallopeptidase 2	Homo sapiens	170-175
28843566-5	2017	To demonstrate the accuracy of our assay, the complex dissociation constants of three known thrombin inhibitors, namely benzamidine, p-aminobenzamidine and nafamostat were determined and found to be in good concordance with the previously reported values.	nafamostat	156-166	coagulation factor II, thrombin	Homo sapiens	92-100
29100036-0	2018	Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.	nafamostat	0-19	interferon gamma	Homo sapiens	61-77
29100036-3	2018	Nafamostat mesilate (NM), a serine protease inhibitor that is frequently used in the clinic, potently suppressed interferon-gamma (IFN-gamma)-induced up-regulation of PD-L1 in cultured human lung cancer cells (HLC-1) at both the messenger RNA (mRNA) and protein levels.	nafamostat	0-19	interferon gamma	Homo sapiens	113-140
29100036-3	2018	Nafamostat mesilate (NM), a serine protease inhibitor that is frequently used in the clinic, potently suppressed interferon-gamma (IFN-gamma)-induced up-regulation of PD-L1 in cultured human lung cancer cells (HLC-1) at both the messenger RNA (mRNA) and protein levels.	nafamostat	0-19	CD274 molecule	Homo sapiens	167-172
29100036-3	2018	Nafamostat mesilate (NM), a serine protease inhibitor that is frequently used in the clinic, potently suppressed interferon-gamma (IFN-gamma)-induced up-regulation of PD-L1 in cultured human lung cancer cells (HLC-1) at both the messenger RNA (mRNA) and protein levels.	nafamostat	0-19	NADH:ubiquinone oxidoreductase subunit C2	Homo sapiens	210-215
29863120-6	2018	Next, we assessed cell viability, apoptotic signal and nuclear factor-kappa B (NF-kappaB) activity in response to treatment with FUT-175 alone and in combination with GSK-3 inhibitor or protein phosphatase 2A (PP2A) by cell proliferation assay, Western blot analysis and enzyme-linked immunosorbent assay.	nafamostat	129-136	nuclear factor kappa B subunit 1	Homo sapiens	55-77
29863120-6	2018	Next, we assessed cell viability, apoptotic signal and nuclear factor-kappa B (NF-kappaB) activity in response to treatment with FUT-175 alone and in combination with GSK-3 inhibitor or protein phosphatase 2A (PP2A) by cell proliferation assay, Western blot analysis and enzyme-linked immunosorbent assay.	nafamostat	129-136	nuclear factor kappa B subunit 1	Homo sapiens	79-88
29863120-6	2018	Next, we assessed cell viability, apoptotic signal and nuclear factor-kappa B (NF-kappaB) activity in response to treatment with FUT-175 alone and in combination with GSK-3 inhibitor or protein phosphatase 2A (PP2A) by cell proliferation assay, Western blot analysis and enzyme-linked immunosorbent assay.	nafamostat	129-136	protein phosphatase 2 phosphatase activator	Homo sapiens	210-214
27322737-4	2016	Here, our study showed that nafamostat mesilate abrogated the constitutive NF-kappaB activation in CRC cells, which is mediated through inhibition of phosphorylation of IkappaBalpha and nuclear translocation of p65.	nafamostat	28-38	NFKB inhibitor alpha	Homo sapiens	169-181
27439606-5	2016	Furthermore, histone H4 cleavage was blocked by the GzmA inhibitor nafamostat mesylate and by GzmA knockdown using siRNA.	nafamostat	67-77	H4 clustered histone 9	Homo sapiens	13-23
27439606-5	2016	Furthermore, histone H4 cleavage was blocked by the GzmA inhibitor nafamostat mesylate and by GzmA knockdown using siRNA.	nafamostat	67-77	granzyme A	Homo sapiens	52-56
27322737-4	2016	Here, our study showed that nafamostat mesilate abrogated the constitutive NF-kappaB activation in CRC cells, which is mediated through inhibition of phosphorylation of IkappaBalpha and nuclear translocation of p65.	nafamostat	28-38	nuclear factor kappa B subunit 1	Homo sapiens	75-84
27322737-4	2016	Here, our study showed that nafamostat mesilate abrogated the constitutive NF-kappaB activation in CRC cells, which is mediated through inhibition of phosphorylation of IkappaBalpha and nuclear translocation of p65.	nafamostat	28-38	RELA proto-oncogene, NF-kB subunit	Homo sapiens	211-214
27322737-5	2016	Also, we found that nafamostat mesilate inhibited phosphorylation of Erk in CRC cells.	nafamostat	20-39	mitogen-activated protein kinase 1	Homo sapiens	69-72
27322737-7	2016	Furthermore, nafamostat mesilate could reverse oxaliplatin induced NF-kappaB and Erk activation in CRC cells, and enhance the sensitivity of CRC cells to oxaliplatin.	nafamostat	13-32	nuclear factor kappa B subunit 1	Homo sapiens	67-76
27322737-7	2016	Furthermore, nafamostat mesilate could reverse oxaliplatin induced NF-kappaB and Erk activation in CRC cells, and enhance the sensitivity of CRC cells to oxaliplatin.	nafamostat	13-32	mitogen-activated protein kinase 1	Homo sapiens	81-84
27322737-9	2016	Overall, our data suggest that nafamostat mesilate, a relatively non-toxic drug that targets NF-kappaB and Erk, may, in combination with oxaliplatin, represent a novel therapeutic strategy for CRC treatment.	nafamostat	31-50	nuclear factor kappa B subunit 1	Homo sapiens	93-102
27322737-9	2016	Overall, our data suggest that nafamostat mesilate, a relatively non-toxic drug that targets NF-kappaB and Erk, may, in combination with oxaliplatin, represent a novel therapeutic strategy for CRC treatment.	nafamostat	31-50	mitogen-activated protein kinase 1	Homo sapiens	107-110
27610041-0	2016	Nafamostat mesilate promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway.	nafamostat	0-19	AKT serine/threonine kinase 1	Homo sapiens	74-77
27610041-0	2016	Nafamostat mesilate promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway.	nafamostat	0-19	nitric oxide synthase 3	Homo sapiens	78-82
26485396-6	2015	Nafamostat achieved complete, nearly stoichiometric and very slowly reversible inhibition of matriptase and tryptase, but inhibited prostasin less potently and was weakest versus HAT.	nafamostat	0-10	serine protease 8	Homo sapiens	132-141
26546875-4	2016	Nafamostat mesilate, a synthetic serine protease inhibitor, inhibits NF-kappaB activation in pancreatic cancer.	nafamostat	0-19	nuclear factor kappa B subunit 1	Homo sapiens	69-78
27059791-7	2016	Co-treatment with either nafamostat or SB431542 blocked the morphologic change and abrogated the increased expression of Cd133, Collagen, Vimentin, and Snail1.	nafamostat	25-35	prominin 1	Homo sapiens	121-126
27059791-7	2016	Co-treatment with either nafamostat or SB431542 blocked the morphologic change and abrogated the increased expression of Cd133, Collagen, Vimentin, and Snail1.	nafamostat	25-35	vimentin	Homo sapiens	138-146
27059791-7	2016	Co-treatment with either nafamostat or SB431542 blocked the morphologic change and abrogated the increased expression of Cd133, Collagen, Vimentin, and Snail1.	nafamostat	25-35	snail family transcriptional repressor 1	Homo sapiens	152-158
27240355-8	2016	Moreover, using the MCT inhibitor nafamostat, tryptase-induced angiogenesis was obviously suppressed both in vitro and in vivo.	nafamostat	34-44	tryptase delta 1	Homo sapiens	20-23
26485396-13	2015	Nafamostat, camostat and aprotinin markedly reduced tryptic activity on the apical surface of cystic fibrosis airway epithelial monolayers, suggesting prostasin as the major source of such activity and supporting strategies targeting prostasin for inactivation.	nafamostat	0-10	serine protease 8	Homo sapiens	151-160
26485396-13	2015	Nafamostat, camostat and aprotinin markedly reduced tryptic activity on the apical surface of cystic fibrosis airway epithelial monolayers, suggesting prostasin as the major source of such activity and supporting strategies targeting prostasin for inactivation.	nafamostat	0-10	serine protease 8	Homo sapiens	234-243
25940319-0	2015	Retraction Note to: Nafamostat mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury.	nafamostat	20-39	high mobility group box 1	Homo sapiens	67-72
26032366-5	2015	Moreover, histone H3 cleavage was blocked by the GzmA inhibitor nafamostat mesylate and by GzmA knockdown using siRNA.	nafamostat	64-74	granzyme A	Homo sapiens	49-53
26346967-0	2015	A Synthetic Serine Protease Inhibitor, Nafamostat Mesilate, Is a Drug Potentially Applicable to the Treatment of Ebola Virus Disease.	nafamostat	39-58	Serine protease inhibitor	Rattus norvegicus	12-37
26346967-7	2015	A synthetic serine protease inhibitor, nafamostat mesilate (NM), reduced the release of CatB from the rat pancreas.	nafamostat	39-58	Serine protease inhibitor	Rattus norvegicus	12-37
25479585-1	2015	OBJECTIVE: The objective of this study was to investigate whether prophylactic administration of nafamostat mesilate reduces the incidence of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP), its efficacy, and risk factors for PEP.	nafamostat	97-116	progestagen associated endometrial protein	Homo sapiens	215-218
25882520-5	2015	First, we used a docking model of the irreversible inhibitor, Nafamostat, bound to the active site of HGFA in order to explore structure activity relationships (SAR).	nafamostat	62-72	HGF activator	Homo sapiens	102-106
25954127-0	2015	Nafamostat Mesilate Inhibits TNF-alpha-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production.	nafamostat	0-19	tumor necrosis factor	Homo sapiens	29-38
25954127-8	2015	These data suggest that NM mitigates TNF-alpha-induced monocyte adhesion and the expression of endothelial cell adhesion molecules, and that the anti-adhesive effect of NM is mediated through the inhibition of p66shc, ROS production, and p38 MAPK activation.	nafamostat	24-26	tumor necrosis factor	Homo sapiens	37-46
25479585-1	2015	OBJECTIVE: The objective of this study was to investigate whether prophylactic administration of nafamostat mesilate reduces the incidence of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP), its efficacy, and risk factors for PEP.	nafamostat	97-116	progestagen associated endometrial protein	Homo sapiens	256-259
25479585-6	2015	Analysis of the 322 patients who had undergone ERCP for the first time (n = 158 in the nafamostat mesilate group; n = 164 in the control group) found that PEP again significantly less frequently occurred in the nafamostat mesilate group (5.7%) than in the control group (13.4%; P = 0.0172).	nafamostat	87-106	progestagen associated endometrial protein	Homo sapiens	155-158
25479585-6	2015	Analysis of the 322 patients who had undergone ERCP for the first time (n = 158 in the nafamostat mesilate group; n = 164 in the control group) found that PEP again significantly less frequently occurred in the nafamostat mesilate group (5.7%) than in the control group (13.4%; P = 0.0172).	nafamostat	211-230	progestagen associated endometrial protein	Homo sapiens	155-158
25479585-7	2015	CONCLUSIONS: Our randomized controlled study suggested that short-term administration of nafamostat mesilate 20 mg may reduce the incidence of PEP.	nafamostat	89-108	progestagen associated endometrial protein	Homo sapiens	143-146
23830367-3	2013	We previously reported that nafamostat mesylate inhibited NF-kappaB activation and induced apoptosis in pancreatic cancer.	nafamostat	28-47	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	58-67
24985053-0	2014	Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition.	nafamostat	0-19	coagulation factor II	Rattus norvegicus	107-115
24985053-5	2014	Thrombin expression and activity in the ipsilateral striatum were increased after ischemia, whereas the administration of nafamostat mesilate significantly inhibited thrombin expression and activity.	nafamostat	122-141	coagulation factor II	Rattus norvegicus	166-174
24985053-9	2014	These results suggest that nafamostat mesilate may have a potential therapeutic role for neuroprotection against focal cerebral ischemia through thrombin inhibition.	nafamostat	27-46	coagulation factor II	Rattus norvegicus	145-153
23830367-4	2013	Therefore, we hypothesized that nafamostat mesylate inhibits gemcitabine-induced NF-kappaB activation and enhances apoptosis induced by gemcitabine in gallbladder cancer.	nafamostat	32-51	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	81-90
23830367-5	2013	MATERIALS AND METHODS: In vitro, we assessed NF-kappaB activation of a gallbladder cancer cell line (NOZ) treated with nafamostat mesylate, gemcitabine, or a combination of both.	nafamostat	119-138	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	45-54
23972653-10	2013	CONCLUSION: Inhibition of NF-kappaB by nafamostat mesilate enhances the antitumor effect of adenoviral vector-mediated TNF-alpha gene therapy for HCC in mice.	nafamostat	39-58	tumor necrosis factor	Mus musculus	119-128
23348695-2	2013	In combination treatment with nafamostat mesilate and oxaliplatin, NF-kappaB activation was inhibited by suppressing IkappaBalpha phosphorylation, and caspase-8-mediated apoptosis was more prominent than that treated with oxaliplatin alone, both in vitro and in vivo.	nafamostat	30-49	NFKB inhibitor alpha	Homo sapiens	117-129
23972653-4	2013	We hypothesized that the NF-kappaB inhibitor nafamostat mesilate would enhance the antitumor effect of adenovirus vector-mediated TNF-alpha gene therapy for HCC.	nafamostat	45-55	tumor necrosis factor	Homo sapiens	130-139
23972653-5	2013	METHODS: In vitro, we assessed the inhibitory effect of nafamostat mesilate on TNF-alpha-induced NF-kappaB activation and enhanced apoptosis in human HCC cell lines (Huh-7 and Hep3B).	nafamostat	56-75	tumor necrosis factor	Homo sapiens	79-88
23348695-2	2013	In combination treatment with nafamostat mesilate and oxaliplatin, NF-kappaB activation was inhibited by suppressing IkappaBalpha phosphorylation, and caspase-8-mediated apoptosis was more prominent than that treated with oxaliplatin alone, both in vitro and in vivo.	nafamostat	30-49	caspase 8	Homo sapiens	151-160
22761302-3	2012	ADV extract-induced scratching was inhibited by the opioid receptor antagonists naloxone and naltrexone, the serine protease inhibitor nafamostat mesylate, and the PAR(2) receptor antagonist FSLLRY-NH(2).	nafamostat	135-154	complement component 1, s subcomponent 1	Mus musculus	109-124
23219147-7	2013	RESULTS: In vitro, FUT175 inhibited both TNF-alpha- and gemcitabine-induced NF-kappaB activation and enhanced induction of apoptosis.	nafamostat	19-25	tumor necrosis factor	Mus musculus	41-50
23219147-7	2013	RESULTS: In vitro, FUT175 inhibited both TNF-alpha- and gemcitabine-induced NF-kappaB activation and enhanced induction of apoptosis.	nafamostat	19-25	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	76-85
23219147-9	2013	CONCLUSIONS: Inhibition of NF-kappaB by FUT175 enhances the antitumor effect of combined TNF-alpha gene therapy and gemcitabine for pancreatic cancer.	nafamostat	40-46	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	27-36
23219147-9	2013	CONCLUSIONS: Inhibition of NF-kappaB by FUT175 enhances the antitumor effect of combined TNF-alpha gene therapy and gemcitabine for pancreatic cancer.	nafamostat	40-46	tumor necrosis factor	Mus musculus	89-98
23219147-3	2013	We hypothesized that nafamostat mesilate (FUT175), an NF-kappaB inhibitor, enhances the antitumor effect of combination treatment with an adenoviral vector-expressing TNF-alpha (AxCAhTNF-alpha) and gemcitabine for pancreatic cancer in mice.	nafamostat	21-40	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	54-63
23219147-3	2013	We hypothesized that nafamostat mesilate (FUT175), an NF-kappaB inhibitor, enhances the antitumor effect of combination treatment with an adenoviral vector-expressing TNF-alpha (AxCAhTNF-alpha) and gemcitabine for pancreatic cancer in mice.	nafamostat	21-40	tumor necrosis factor	Mus musculus	167-176
23219147-3	2013	We hypothesized that nafamostat mesilate (FUT175), an NF-kappaB inhibitor, enhances the antitumor effect of combination treatment with an adenoviral vector-expressing TNF-alpha (AxCAhTNF-alpha) and gemcitabine for pancreatic cancer in mice.	nafamostat	42-48	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	54-63
23219147-3	2013	We hypothesized that nafamostat mesilate (FUT175), an NF-kappaB inhibitor, enhances the antitumor effect of combination treatment with an adenoviral vector-expressing TNF-alpha (AxCAhTNF-alpha) and gemcitabine for pancreatic cancer in mice.	nafamostat	42-48	tumor necrosis factor	Mus musculus	167-176
23219147-4	2013	STUDY DESIGN: In vitro, we assessed that FUT175 inhibited both TNF-alpha- and gemcitabine-induced NF-kappaB activation and enhanced apoptosis in human pancreatic cancer cell lines (MIAPaCa-2 and AsPC-1).	nafamostat	41-47	tumor necrosis factor	Homo sapiens	63-72
23219147-4	2013	STUDY DESIGN: In vitro, we assessed that FUT175 inhibited both TNF-alpha- and gemcitabine-induced NF-kappaB activation and enhanced apoptosis in human pancreatic cancer cell lines (MIAPaCa-2 and AsPC-1).	nafamostat	41-47	nuclear factor kappa B subunit 1	Homo sapiens	98-107
22806547-4	2013	AIMS: The purpose of this study was to prove that addition of nafamostat mesilate (FUT-175), a synthetic serine protease inhibitor and an NF-kappaB inhibitor, to i.p.	nafamostat	62-81	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	138-147
22806547-6	2013	METHODS: In vitro, we assessed NF-kappaB activity and apoptosis in response to treatment with FUT-175 alone, paclitaxel alone, or a combination of FUT-175 and paclitaxel in a human gastric cancer cell line (MKN-45).	nafamostat	94-101	nuclear factor kappa B subunit 1	Homo sapiens	31-40
22806547-6	2013	METHODS: In vitro, we assessed NF-kappaB activity and apoptosis in response to treatment with FUT-175 alone, paclitaxel alone, or a combination of FUT-175 and paclitaxel in a human gastric cancer cell line (MKN-45).	nafamostat	147-154	nuclear factor kappa B subunit 1	Homo sapiens	31-40
22067907-8	2012	Treatment with FUT-175 (10 mg/kg), a potent serine protease inhibitor, increased survival after I-R, inhibited tissue protease activity, and significantly decreased intestinal myeloperoxidase (MPO) activity and chemokine and adhesion molecule expression.	nafamostat	15-22	complement component 1, s subcomponent 1	Mus musculus	44-59
22067907-8	2012	Treatment with FUT-175 (10 mg/kg), a potent serine protease inhibitor, increased survival after I-R, inhibited tissue protease activity, and significantly decreased intestinal myeloperoxidase (MPO) activity and chemokine and adhesion molecule expression.	nafamostat	15-22	myeloperoxidase	Mus musculus	176-191
22067907-8	2012	Treatment with FUT-175 (10 mg/kg), a potent serine protease inhibitor, increased survival after I-R, inhibited tissue protease activity, and significantly decreased intestinal myeloperoxidase (MPO) activity and chemokine and adhesion molecule expression.	nafamostat	15-22	myeloperoxidase	Mus musculus	193-196
20820824-0	2011	Nafamostat mesilate, a potent tryptase inhibitor, modulates periodontitis in rats.	nafamostat	0-19	tryptase alpha/beta 1	Rattus norvegicus	30-38
20499255-0	2010	Pretreatment with nafamostat mesilate, a kallikrein inhibitor, to decrease withdrawal response associated with rocuronium.	nafamostat	18-37	serine peptidase inhibitor Kazal type 6	Homo sapiens	41-61
21828194-3	2011	Guided by the close molecular relation of BLINaC to acid-sensing ion channels, we discovered in this study that rat BLINaC (rBLINaC) and mouse BLINaC are inhibited by micromolar concentrations of diarylamidines and nafamostat, similar to acid-sensing ion channels.	nafamostat	215-225	acid sensing ion channel subunit family member 5	Rattus norvegicus	42-48
21828194-3	2011	Guided by the close molecular relation of BLINaC to acid-sensing ion channels, we discovered in this study that rat BLINaC (rBLINaC) and mouse BLINaC are inhibited by micromolar concentrations of diarylamidines and nafamostat, similar to acid-sensing ion channels.	nafamostat	215-225	acid sensing ion channel subunit family member 5	Rattus norvegicus	116-122
21828194-3	2011	Guided by the close molecular relation of BLINaC to acid-sensing ion channels, we discovered in this study that rat BLINaC (rBLINaC) and mouse BLINaC are inhibited by micromolar concentrations of diarylamidines and nafamostat, similar to acid-sensing ion channels.	nafamostat	215-225	acid sensing ion channel subunit family member 5	Rattus norvegicus	124-131
21828194-3	2011	Guided by the close molecular relation of BLINaC to acid-sensing ion channels, we discovered in this study that rat BLINaC (rBLINaC) and mouse BLINaC are inhibited by micromolar concentrations of diarylamidines and nafamostat, similar to acid-sensing ion channels.	nafamostat	215-225	acid-sensing (proton-gated) ion channel family member 5	Mus musculus	116-122
20811662-4	2010	In vitro, nafamostat mesilate inhibited NF-kappaB activation of human pancreatic cancer cell line (Panc-1) by suppressing IkappaBalpha phosphorylation and induced caspase-8 mediated apoptosis.	nafamostat	10-29	pancreas protein 1	Mus musculus	99-105
20811662-4	2010	In vitro, nafamostat mesilate inhibited NF-kappaB activation of human pancreatic cancer cell line (Panc-1) by suppressing IkappaBalpha phosphorylation and induced caspase-8 mediated apoptosis.	nafamostat	10-29	NFKB inhibitor alpha	Homo sapiens	122-134
20811662-4	2010	In vitro, nafamostat mesilate inhibited NF-kappaB activation of human pancreatic cancer cell line (Panc-1) by suppressing IkappaBalpha phosphorylation and induced caspase-8 mediated apoptosis.	nafamostat	10-29	caspase 8	Homo sapiens	163-172
21484229-0	2011	Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition.	nafamostat	0-19	nuclear factor kappa B subunit 1	Homo sapiens	110-132
21484229-3	2011	We previously reported that nafamostat mesilate, a synthetic serine protease inhibitor, blocks NF-kappaB activation in pancreatic cancer.	nafamostat	28-47	nuclear factor kappa B subunit 1	Homo sapiens	95-104
21484229-8	2011	RESULTS: In vitro, nafamostat mesilate inhibited activities of NF-kappaB, phosphorylated IkappaBalpha, ICAM-1, VEGF and MMP-9.	nafamostat	19-38	nuclear factor kappa B subunit 1	Homo sapiens	63-72
21484229-8	2011	RESULTS: In vitro, nafamostat mesilate inhibited activities of NF-kappaB, phosphorylated IkappaBalpha, ICAM-1, VEGF and MMP-9.	nafamostat	19-38	NFKB inhibitor alpha	Homo sapiens	89-101
21484229-8	2011	RESULTS: In vitro, nafamostat mesilate inhibited activities of NF-kappaB, phosphorylated IkappaBalpha, ICAM-1, VEGF and MMP-9.	nafamostat	19-38	intercellular adhesion molecule 1	Homo sapiens	103-109
21484229-8	2011	RESULTS: In vitro, nafamostat mesilate inhibited activities of NF-kappaB, phosphorylated IkappaBalpha, ICAM-1, VEGF and MMP-9.	nafamostat	19-38	vascular endothelial growth factor A	Homo sapiens	111-115
21484229-8	2011	RESULTS: In vitro, nafamostat mesilate inhibited activities of NF-kappaB, phosphorylated IkappaBalpha, ICAM-1, VEGF and MMP-9.	nafamostat	19-38	matrix metallopeptidase 9	Homo sapiens	120-125
21482023-4	2011	In vitro, nafamostat mesilate inhibited TNF-alpha-induced NF-kappaB activation and enhanced TNF-alpha-induced apoptosis in human cancer cell line (MIAPaCa-2).	nafamostat	10-29	tumor necrosis factor	Homo sapiens	40-49
21482023-4	2011	In vitro, nafamostat mesilate inhibited TNF-alpha-induced NF-kappaB activation and enhanced TNF-alpha-induced apoptosis in human cancer cell line (MIAPaCa-2).	nafamostat	10-29	tumor necrosis factor	Homo sapiens	92-101
21122141-2	2010	Here we report that a synthetic serine protease inhibitor, nafamostat mesylate (NM), and several of its analogues, block recombinant TRPM7 currents expressed in HEK293T cells in inverse relationship to the concentration of extracellular divalent cations.	nafamostat	59-78	transient receptor potential cation channel subfamily M member 7	Homo sapiens	133-138
20499255-1	2010	PURPOSE: This randomized, double-blind, placebo-controlled study was conducted to examine the preventive effect of nafamostat mesilate, a kallikrein inhibitor, on the withdrawal response associated with rocuronium injection.	nafamostat	115-134	serine peptidase inhibitor Kazal type 6	Homo sapiens	138-158
20536401-6	2009	A patient with AL-amyloidosis, who had bleeding diathesis and excessive fibrinolysis with hypofibrinogenemia, was treated with nafamostat mesilate, a potential inhibitor of uPA.	nafamostat	127-146	plasminogen activator, urokinase	Homo sapiens	173-176
19812969-2	2010	We, therefore, examined whether nafamostat mesilate (FUT), a serine protease inhibitor, can reduce ICH-induced brain injury.	nafamostat	32-51	Serine protease inhibitor	Rattus norvegicus	61-86
17624024-8	2007	In addition, the palmitoyl-CoA hydrolytic activity was competitively inhibited by nafamostat with the apparent Ki value of 164 microM for the liver cytosol from HL-2.	nafamostat	82-92	intelectin 2	Homo sapiens	161-165
18602161-5	2008	Nanotube-mediated C4d elevation in C1q-depleted serum, however, was inhibited by N-acetylglucosamine, Futhan (a broad-spectrum serine protease inhibitor capable of preventing complement activation through all three pathways) and anti-MASP-2 antibodies; this strongly suggests a role for activation of MASP-2 in subsequent C4 cleavage and assembly of C4b2a covertases.	nafamostat	102-108	MBL associated serine protease 2	Rattus norvegicus	234-240
18602161-5	2008	Nanotube-mediated C4d elevation in C1q-depleted serum, however, was inhibited by N-acetylglucosamine, Futhan (a broad-spectrum serine protease inhibitor capable of preventing complement activation through all three pathways) and anti-MASP-2 antibodies; this strongly suggests a role for activation of MASP-2 in subsequent C4 cleavage and assembly of C4b2a covertases.	nafamostat	102-108	MBL associated serine protease 2	Rattus norvegicus	301-307
17414427-0	2007	Nafamostat mesilate inhibits high-mobility group box 1 by lipopolysaccharide stimulation in murine macrophage RAW 264.7.	nafamostat	0-19	high mobility group box 1	Mus musculus	29-54
19008643-0	2008	Nafamostat mesilate, a potent serine protease inhibitor, inhibits airway eosinophilic inflammation and airway epithelial remodeling in a murine model of allergic asthma.	nafamostat	0-19	complement component 1, s subcomponent 1	Mus musculus	30-45
19008643-7	2008	Nafamostat mesilate also dose-dependently inhibited increases in the levels of interleukin-13 and eotaxin in BALF and goblet cell hyperplasia.	nafamostat	0-19	interleukin 13	Mus musculus	79-93
19008643-7	2008	Nafamostat mesilate also dose-dependently inhibited increases in the levels of interleukin-13 and eotaxin in BALF and goblet cell hyperplasia.	nafamostat	0-19	chemokine (C-C motif) ligand 11	Mus musculus	98-105
16702735-10	2006	These results suggest that human arylesterases and carboxylesterase 2 may be predominantly responsible for the metabolism of nafamostat in the blood and liver, respectively.	nafamostat	125-135	carboxylesterase 2	Homo sapiens	51-69
17458645-0	2007	Nafamostat mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury.	nafamostat	0-19	high mobility group box 1	Rattus norvegicus	47-52
16815145-2	2006	OBJECTIVE: We sought to investigate the effects of serine protease inhibitors nafamostat mesilate (FUT), gabexate mesilate (FOY), and ulinastatin (UTI) on airway inflammation in a mouse model of allergic asthma.	nafamostat	78-97	complement component 1, s subcomponent 1	Mus musculus	51-66
16359660-0	2006	Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice.	nafamostat	113-132	tryptase alpha/beta 1	Mus musculus	30-38
16612309-0	2006	Nafamostat attenuated the impairment of fibrinolysis in animal sepsis model by suppressing the increase of plasminogen activator inhibitor type 1.	nafamostat	0-10	serpin family E member 2	Rattus norvegicus	107-145
16552341-6	2006	TAP generation was also inhibited by pretreatment with serine protease inhibitor FUT-175 (1 micromol/L) but not cysteine protease inhibitor E64 (0.1 mmol/L) or E64-d (0.1 mmol/L).	nafamostat	81-88	cell division cycle 34, ubiqiutin conjugating enzyme	Rattus norvegicus	55-70
16359660-1	2006	The pruritogenic potency of tryptase and its involvement in anti-pruritic effect of intravenous nafamostat mesilate (NFM) were studied in mice.	nafamostat	96-115	tryptase alpha/beta 1	Mus musculus	28-36
16359660-4	2006	NFM (10 mg/kg) inhibited scratching induced by tryptase but not by histamine and serotonin.	nafamostat	0-3	tryptase alpha/beta 1	Mus musculus	47-55
16359660-7	2006	NFM (10 mg/kg) suppressed tryptase activity in the mouse skin.	nafamostat	0-3	tryptase alpha/beta 1	Mus musculus	26-34
16093612-0	2005	Nafamostat mesilate induces production of interleukin-12 and -18 in human peripheral blood mononuclear cells.	nafamostat	0-19	interleukin 18	Homo sapiens	42-64
16260585-4	2005	The IL-18 induction was decreased significantly by coadministration of a serine protease inhibitor [Nafamostat mesilate (FUT-175)] with LPS.	nafamostat	100-119	interleukin 18	Mus musculus	4-9
16093612-2	2005	We found that nafamostat mesilate elicits IL-12, IL-18, tumor necrosis factor-alpha and interferon-gamma production, and the expression of intercellular adhesion molecules-1, B7.1, B7.2, CD40, and CD40 ligand in human peripheral blood mononuclear cells.	nafamostat	14-33	interleukin 18	Homo sapiens	49-54
16093612-2	2005	We found that nafamostat mesilate elicits IL-12, IL-18, tumor necrosis factor-alpha and interferon-gamma production, and the expression of intercellular adhesion molecules-1, B7.1, B7.2, CD40, and CD40 ligand in human peripheral blood mononuclear cells.	nafamostat	14-33	tumor necrosis factor	Homo sapiens	56-83
16093612-2	2005	We found that nafamostat mesilate elicits IL-12, IL-18, tumor necrosis factor-alpha and interferon-gamma production, and the expression of intercellular adhesion molecules-1, B7.1, B7.2, CD40, and CD40 ligand in human peripheral blood mononuclear cells.	nafamostat	14-33	interferon gamma	Homo sapiens	88-104
16093612-2	2005	We found that nafamostat mesilate elicits IL-12, IL-18, tumor necrosis factor-alpha and interferon-gamma production, and the expression of intercellular adhesion molecules-1, B7.1, B7.2, CD40, and CD40 ligand in human peripheral blood mononuclear cells.	nafamostat	14-33	CD40 molecule	Homo sapiens	187-191
16093612-2	2005	We found that nafamostat mesilate elicits IL-12, IL-18, tumor necrosis factor-alpha and interferon-gamma production, and the expression of intercellular adhesion molecules-1, B7.1, B7.2, CD40, and CD40 ligand in human peripheral blood mononuclear cells.	nafamostat	14-33	CD40 molecule	Homo sapiens	197-201
15894839-3	2004	Naf caused a significant decrease in Ald secretion rate compared to saline (1.99+/-0.32 vs. 3.42+/-0.56 ng/min, p <0.001), while adrenal blood flow, mean arterial pressure and plasma renin activity in the adrenal venous blood did not differ between the two groups.	nafamostat	0-3	renin	Rattus norvegicus	186-191
15655299-5	2005	In cultured endothelial cells of human pulmonary artery and bovine aorta, RCM, when applied in combination with mast cells, disrupts barrier function evaluated by the permeability of Evans blue through a monolayer of cultured cells, which is blocked by nafamostat and mimicked by tryptase and PAR-2-activating peptide.	nafamostat	253-263	F2R like trypsin receptor 1	Bos taurus	293-298
12890431-1	2003	Nafamostat mesilate (NM), a clinically used serine protease inhibitor, suppressed the overproduction of nitric oxide (NO) and the expression of inducible nitric oxide synthase (iNOS) in RAW264.7 murine macrophages treated with lipopolysaccharide (LPS, 100 ng/ml); however, it had little effect on endothelial NOS (eNOS) in human umbilical vein endothelial cells (HUVEC).	nafamostat	0-19	nitric oxide synthase 2, inducible	Mus musculus	144-175
12890431-1	2003	Nafamostat mesilate (NM), a clinically used serine protease inhibitor, suppressed the overproduction of nitric oxide (NO) and the expression of inducible nitric oxide synthase (iNOS) in RAW264.7 murine macrophages treated with lipopolysaccharide (LPS, 100 ng/ml); however, it had little effect on endothelial NOS (eNOS) in human umbilical vein endothelial cells (HUVEC).	nafamostat	0-19	nitric oxide synthase 2, inducible	Mus musculus	177-181
12890431-1	2003	Nafamostat mesilate (NM), a clinically used serine protease inhibitor, suppressed the overproduction of nitric oxide (NO) and the expression of inducible nitric oxide synthase (iNOS) in RAW264.7 murine macrophages treated with lipopolysaccharide (LPS, 100 ng/ml); however, it had little effect on endothelial NOS (eNOS) in human umbilical vein endothelial cells (HUVEC).	nafamostat	0-19	nitric oxide synthase 3, endothelial cell	Mus musculus	297-312
12890431-3	2003	Western blotting showed that nafamostat mesilate suppressed the phosphorylation and degradation of inhibitor kappaB-alpha (IkappaB-alpha), which holds NF-kappaB in the cytoplasm in an inactivated state.	nafamostat	29-48	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	123-136
12890431-4	2003	Our observations suggest that nafamostat mesilate is a candidate agent for various diseases such as ischemia-reperfusion, graft rejection, inflammatory diseases, and autoimmune diseases, in which iNOS and/or NF-kappaB are upregulated.	nafamostat	30-49	nitric oxide synthase 2, inducible	Mus musculus	196-200
12744489-2	2003	Male Sprague-Dawley rats were administrated the serine protease inhibitor (6-amidino-2-naphthyl p-guanidinobenzoate dimethanesulfate, Nafamostat) either intraluminally into the gut or intravenously after a laparotomy (trauma) and then subjected to 90 min of hemorrhagic shock (T/HS) or sham shock (T/SS).	nafamostat	134-144	kallikrein 1-related peptidase C8	Rattus norvegicus	48-63
11294265-7	2001	In case 3, complicated by massive intra-abdominal hemorrhage during ECMO, anticoagulants were changed from heparin alone to combined use with nafamostat mesilate, a thrombin inhibitor with a very short half-life.	nafamostat	142-161	coagulation factor II, thrombin	Homo sapiens	165-173
12642398-0	2003	A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium.	nafamostat	28-47	tryptase alpha/beta 1	Rattus norvegicus	9-17
12642398-3	2003	(3) Both gabexate mesilate and nafamostat mesilate inhibited the activity of purified human lung tryptase, although the latter compound was far more potent than the former.	nafamostat	31-50	tryptase alpha/beta 1	Rattus norvegicus	97-105
12642398-7	2003	These effects of tryptase and ioxaglate were reversed by nafamostat mesilate.	nafamostat	57-76	tryptase alpha/beta 1	Rattus norvegicus	17-25
12642398-9	2003	Both of these actions of tryptase and ioxaglate were reversed by nafamostat mesilate.	nafamostat	65-84	tryptase alpha/beta 1	Rattus norvegicus	25-33
12506133-4	2003	A synthetic serine protease inhibitor, nafamostat mesilate (NM), which is commonly used for the treatment of pancreatitis and disseminated intravascular coagulation in Japan, also inhibited the secretion of prostasin in M-1 cells.	nafamostat	39-58	cell division cycle 34, ubiqiutin conjugating enzyme	Rattus norvegicus	12-27
12506133-4	2003	A synthetic serine protease inhibitor, nafamostat mesilate (NM), which is commonly used for the treatment of pancreatitis and disseminated intravascular coagulation in Japan, also inhibited the secretion of prostasin in M-1 cells.	nafamostat	39-58	serine protease 8	Rattus norvegicus	207-216
12592100-9	2002	Moreover, treatment with Pefabloc as well as another serine protease inhibitor, FUT175, inhibited CCK-induced IKK activation.	nafamostat	80-86	cholecystokinin	Rattus norvegicus	98-101
12203894-16	2002	Treatment with FUT-175 preserved significantly superoxide dismutase precursor and alphaB-crystallin protein expression when compared to vehicle animals.	nafamostat	15-22	alpha-crystallin B chain	Oryctolagus cuniculus	82-99
11958287-7	2000	As for anticoagulants, nafamostat mesylate (NM) completely suppressed the rise in plasma MPO during HD with cuprophane.	nafamostat	23-42	myeloperoxidase	Homo sapiens	89-92
10430784-5	1999	Futhan/EDTA prevented C3a and C4a generation in blood and plasma samples held at room temperature (22-23 degrees C) for 1 h and in plasma held for 24 h at 4 degrees C or -70 degrees C. The mean C3a concentration (1.76 mg/L; n = 19) at time 0 in EDTA plasma samples from liver transplant patients was significantly higher than for controls (0.34 mg/L; n = 11).	nafamostat	0-6	complement C3	Homo sapiens	22-25
10954057-4	2000	LPS also stimulated secretion of IL-6 and IL-8 in cultured trophoblasts, which was suppressed by nafamostat mesilate.	nafamostat	97-116	interleukin 6	Homo sapiens	33-37
10954057-4	2000	LPS also stimulated secretion of IL-6 and IL-8 in cultured trophoblasts, which was suppressed by nafamostat mesilate.	nafamostat	97-116	C-X-C motif chemokine ligand 8	Homo sapiens	42-46
10655909-5	1999	Propofol and its lipid solvent mixed with blood produced approximately two-fold generation of bradykinin compared with the saline control, and this was inhibited completely by nafamostat and lidocaine.	nafamostat	176-186	kininogen 1	Homo sapiens	94-104
10430784-5	1999	Futhan/EDTA prevented C3a and C4a generation in blood and plasma samples held at room temperature (22-23 degrees C) for 1 h and in plasma held for 24 h at 4 degrees C or -70 degrees C. The mean C3a concentration (1.76 mg/L; n = 19) at time 0 in EDTA plasma samples from liver transplant patients was significantly higher than for controls (0.34 mg/L; n = 11).	nafamostat	0-6	complement C4A (Rodgers blood group)	Homo sapiens	30-33
10430784-5	1999	Futhan/EDTA prevented C3a and C4a generation in blood and plasma samples held at room temperature (22-23 degrees C) for 1 h and in plasma held for 24 h at 4 degrees C or -70 degrees C. The mean C3a concentration (1.76 mg/L; n = 19) at time 0 in EDTA plasma samples from liver transplant patients was significantly higher than for controls (0.34 mg/L; n = 11).	nafamostat	0-6	complement C3	Homo sapiens	194-197
10430784-7	1999	In the patients, C3a concentrations were lower in Futhan/EDTA plasma than in EDTA at time 0 and after 60 min at room temperature (1.40 and 2.02 mg/L, respectively).	nafamostat	50-56	complement C3	Homo sapiens	17-20
10430784-9	1999	The mean patient C4a was 0.83 mg/L in Futhan/EDTA plasma at time 0 vs 0.1 mg/L for controls.	nafamostat	38-44	complement C4A (Rodgers blood group)	Homo sapiens	17-20
7836734-7	1994	In experiment 2 the increase in Ang II level after 30 min exercise in the NAF(+) group was significantly lower than in the NAF(-) group.	nafamostat	74-77	angiotensinogen	Homo sapiens	32-38
10066865-2	1999	We examined the effect of the synthetic serine protease inhibitor FUT-175 (developed as a potent inhibitor of thrombin and the complement system) on vascular lesions using balloon dilatation-induced neointimal formation in the carotid artery of rats.	nafamostat	66-73	coagulation factor II	Rattus norvegicus	110-118
9032217-1	1997	Nafamostat mesilate (NM) is a synthetic protease inhibitor that is capable of inhibiting the various coagulation factors such as factor VIIa and thrombin.	nafamostat	0-19	coagulation factor II	Rattus norvegicus	145-153
7763192-0	1995	Effect of nafamostat mesilate on bradykinin generation and hemodynamics during LDL apheresis.	nafamostat	10-29	kininogen 1	Homo sapiens	33-43
16801094-1	1999	We found that nafamostat mesilate (NM) inhibits platelet aggregation induced by all agonists tested, including ADP, collagen, arachidonic acid, thromboxane A analog, A23187, phorbol 12-myristate 13-acetate (PMA), NaF and thrombin.	nafamostat	14-33	C-X-C motif chemokine ligand 8	Homo sapiens	213-216
16801094-1	1999	We found that nafamostat mesilate (NM) inhibits platelet aggregation induced by all agonists tested, including ADP, collagen, arachidonic acid, thromboxane A analog, A23187, phorbol 12-myristate 13-acetate (PMA), NaF and thrombin.	nafamostat	14-33	coagulation factor II, thrombin	Homo sapiens	221-229
10440571-1	1999	We investigated the effect of FUT-175, a serine protease inhibitor, on the production of pro-inflammatory cytokines, interleukin-6 (IL-6) and interleukin-8 (IL-8), by monocytes stimulated with lipopolysaccharide (LPS).	nafamostat	30-37	interleukin 6	Homo sapiens	117-130
10440571-1	1999	We investigated the effect of FUT-175, a serine protease inhibitor, on the production of pro-inflammatory cytokines, interleukin-6 (IL-6) and interleukin-8 (IL-8), by monocytes stimulated with lipopolysaccharide (LPS).	nafamostat	30-37	interleukin 6	Homo sapiens	132-136
10440571-1	1999	We investigated the effect of FUT-175, a serine protease inhibitor, on the production of pro-inflammatory cytokines, interleukin-6 (IL-6) and interleukin-8 (IL-8), by monocytes stimulated with lipopolysaccharide (LPS).	nafamostat	30-37	C-X-C motif chemokine ligand 8	Homo sapiens	142-155
10440571-1	1999	We investigated the effect of FUT-175, a serine protease inhibitor, on the production of pro-inflammatory cytokines, interleukin-6 (IL-6) and interleukin-8 (IL-8), by monocytes stimulated with lipopolysaccharide (LPS).	nafamostat	30-37	C-X-C motif chemokine ligand 8	Homo sapiens	157-161
9128326-5	1997	nafamostat mesilate and underwent selective embolization of the arteries feeding the hemangioma; consequently, the plasma fibrinogen concentration increased to 1.6-fold before surgery.	nafamostat	0-19	fibrinogen beta chain	Homo sapiens	122-132
9127328-0	1997	Active inhibitory effect of nafamostat mesylate against the elevation of plasma myeloperoxidase during hemodialysis.	nafamostat	28-47	myeloperoxidase	Homo sapiens	80-95
9127328-11	1997	These ex vivo results indicate that NM has an active inhibitory effect on the elevation of plasma MPO induced by granulocyte activation through a dialysis membrane.	nafamostat	36-38	myeloperoxidase	Homo sapiens	98-101
9127328-12	1997	Our results demonstrate that clinical use of NM as an anticoagulant serves to selectively suppress MPO elevation considered as a consequence of granulocyte activation during HD.	nafamostat	45-47	myeloperoxidase	Homo sapiens	99-102
7620820-0	1995	Inhibitory effect of FUT-175 on the production of interleukin 8 and polymorphonuclear leukocyte elastase.	nafamostat	21-28	C-X-C motif chemokine ligand 8	Homo sapiens	50-63
7620820-0	1995	Inhibitory effect of FUT-175 on the production of interleukin 8 and polymorphonuclear leukocyte elastase.	nafamostat	21-28	elastase, neutrophil expressed	Homo sapiens	86-104
7836734-7	1994	In experiment 2 the increase in Ang II level after 30 min exercise in the NAF(+) group was significantly lower than in the NAF(-) group.	nafamostat	123-126	angiotensinogen	Homo sapiens	32-38
8029816-0	1994	Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity.	nafamostat	10-29	coagulation factor III, tissue factor	Homo sapiens	66-79
7816751-3	1994	The cytosolic SOD enzyme activity in fibroblasts exposed to superoxide anions 24 h after treatment with EGF plus nafamostat (NM), a potent protease inhibitor, was increased 1.6-fold compared to control-treated cells.	nafamostat	113-123	epidermal growth factor like 1	Rattus norvegicus	104-107
7959424-3	1994	In trypsin-taurocholate-induced pancreatic injury, E3123 and nafamostat mesilate suppressed the leakage of lipase at concentrations of 0.1-1 microM and 1-10 microM, respectively.	nafamostat	61-80	lipase G, endothelial type	Rattus norvegicus	107-113
7959424-5	1994	Exposure of a rat pancreatic slice to phospholipase A2 also caused the leakage of pancreatic enzyme, while the inhibition of enzyme leakage by E3123 was similar to that observed in the isolated, perfused pancreas; nafamostat mesilate was not effective.	nafamostat	214-233	phospholipase A2 group IB	Rattus norvegicus	38-54
2050602-5	1991	In two patients, preoperative anticoagulation with either heparin or nafamostat mesilate was followed by an increase in plasma fibrinogen level from 0.7 to 5.6 g/L and a decrease in FDP from 64 to 8 micrograms/ml in one patient, and fibrinogen from 1.0 to 2.8 g/L and FDP from 40 to 5 micrograms/mL in another patient.	nafamostat	69-79	fibrinogen beta chain	Homo sapiens	127-137
1989498-1	1991	The synthetic antiprotease, FUT-175 (6-amidino-2-naphthyl-4-guanidinobenzoate), was found to be an extraordinarily potent and rapid inhibitor of human Q31 cytotoxic T-lymphocyte granzyme A.	nafamostat	37-77	granzyme A	Homo sapiens	178-188
8312873-0	1993	Cytoprotective effects of epidermal growth factor (EGF) ointment containing nafamostat, a protease inhibitor, on tissue damage at burn sites in rats.	nafamostat	76-86	epidermal growth factor like 1	Rattus norvegicus	26-49
8312873-0	1993	Cytoprotective effects of epidermal growth factor (EGF) ointment containing nafamostat, a protease inhibitor, on tissue damage at burn sites in rats.	nafamostat	76-86	epidermal growth factor like 1	Rattus norvegicus	51-54
8312873-1	1993	When epidermal growth factor (EGF) ointment containing a protease inhibitor, nafamostat (NM), was applied to burn sites in rats, the superoxide dismutase (SOD) enzyme activity and protein content increased 45% and 60%, respectively, at these sites 1 d after the burns compared with the control ointment.	nafamostat	77-87	epidermal growth factor like 1	Rattus norvegicus	5-28
8312873-1	1993	When epidermal growth factor (EGF) ointment containing a protease inhibitor, nafamostat (NM), was applied to burn sites in rats, the superoxide dismutase (SOD) enzyme activity and protein content increased 45% and 60%, respectively, at these sites 1 d after the burns compared with the control ointment.	nafamostat	77-87	epidermal growth factor like 1	Rattus norvegicus	30-33
1521904-3	1992	Although the bradykinin concentration was markedly increased by passing the plasma through the column, this increment was suppressed by nafamostat mesilate which inhibits the initial contact phase of the intrinsic coagulation pathway.	nafamostat	136-155	kininogen 1	Homo sapiens	13-23
1560570-0	1992	[Effect of nafamostat mesilate on the renin-aldosterone system].	nafamostat	11-30	renin	Homo sapiens	38-43
1768503-0	1991	Effect of nafamostat mesilate on bradykinin generation during low-density lipoprotein apheresis using a dextran sulfate cellulose column.	nafamostat	10-29	kininogen 1	Homo sapiens	33-43
2050602-5	1991	In two patients, preoperative anticoagulation with either heparin or nafamostat mesilate was followed by an increase in plasma fibrinogen level from 0.7 to 5.6 g/L and a decrease in FDP from 64 to 8 micrograms/ml in one patient, and fibrinogen from 1.0 to 2.8 g/L and FDP from 40 to 5 micrograms/mL in another patient.	nafamostat	69-79	fibrinogen beta chain	Homo sapiens	233-243
1861238-2	1991	Effect of protease inhibitor, nafamostat, on stabilization and efficacy of EGF in burn.	nafamostat	30-40	epidermal growth factor	Homo sapiens	75-78
34890965-0	2022	Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression.	nafamostat	0-19	cyclin dependent kinase 4	Homo sapiens	101-105
2128896-2	1990	Effect of nafamostat, gabexate, or gelatin on stabilization and efficacy of EGF.	nafamostat	10-20	epidermal growth factor	Homo sapiens	76-79
2128896-6	1990	Significant increases in the dry weight of the wound site granulation tissue, uronic acid (as an index of acid mucopolysaccharide) and hydroxyproline (as an index of collagen) were observed by treatment with EGF ointment containing nafamostat compared with the controls.	nafamostat	232-242	epidermal growth factor	Homo sapiens	208-211
2128896-9	1990	The degradation of 125I-EGF in wound tissue homogenate was significantly decreased in the presence of a protease inhibitor, such as nafamostat or gabexate, or gelatin.	nafamostat	132-142	epidermal growth factor	Homo sapiens	24-27
34924132-8	2022	Nafamostat exerted no significant effect on the SAH grade or cerebral blood flow; however, it improved the neurological behavior and suppressed the thrombin and MMP-9 expression.	nafamostat	0-10	coagulation factor II	Mus musculus	148-156
34924132-8	2022	Nafamostat exerted no significant effect on the SAH grade or cerebral blood flow; however, it improved the neurological behavior and suppressed the thrombin and MMP-9 expression.	nafamostat	0-10	matrix metallopeptidase 9	Mus musculus	161-166
34924132-9	2022	In addition, nafamostat suppressed the ICAM-1 expression and p38 phosphorylation in the in vitro study.	nafamostat	13-23	intercellular adhesion molecule 1	Mus musculus	39-45
34924132-9	2022	In addition, nafamostat suppressed the ICAM-1 expression and p38 phosphorylation in the in vitro study.	nafamostat	13-23	mitogen-activated protein kinase 14	Mus musculus	61-64
34890965-8	2022	Nafamostat mesylate might be an essential adjuvant or alternative drug for the treatment of endocrine-resistant ERPBC due to the low cost-efficiency of the CDK4/6 inhibitor.	nafamostat	0-19	cyclin dependent kinase 4	Homo sapiens	156-162
34924132-10	2022	Nafamostat has a protective effect against HBMVEC after exposure to thrombin and hypoxia, suggesting its role in improving the neurological outcomes after SAH.	nafamostat	0-10	coagulation factor II	Mus musculus	68-76
34890965-0	2022	Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression.	nafamostat	0-19	cyclin dependent kinase 6	Homo sapiens	110-114
34890965-5	2022	We found that nafamostat mesylate, clinically used for patients with pancreatitis and disseminated intravascular coagulation, acts as an anti-cancer drug for endocrine-resistant estrogen receptor-positive breast cancer (ERPBC).	nafamostat	14-33	estrogen receptor 1	Homo sapiens	178-195
34890965-6	2022	Epigenetic repression of CDK4 and CDK6 by nafamostat mesylate induced apoptosis and suppressed the metastasis of ERPBC through the deacetylation of Histone 3 Lysine 27.	nafamostat	42-61	cyclin dependent kinase 4	Homo sapiens	25-29
34890965-6	2022	Epigenetic repression of CDK4 and CDK6 by nafamostat mesylate induced apoptosis and suppressed the metastasis of ERPBC through the deacetylation of Histone 3 Lysine 27.	nafamostat	42-61	cyclin dependent kinase 6	Homo sapiens	34-38
34406858-4	2021	Similarly, inhibition of TMPRSS2 protease activity by camostat mesylate or nafamostat mesylate prevents infection mediated by the TMPRSS2-dependent and cathepsin-independent pathway.	nafamostat	75-94	transmembrane serine protease 2	Homo sapiens	25-32
34787160-4	2021	Thus, four potential drugs (bromhexine, camostat, gabexate, and nafamostat) were used to explore the mechanism of binding with TMPRSS2 in this work.	nafamostat	64-74	transmembrane serine protease 2	Homo sapiens	127-134
34787160-6	2021	Through the results of calculating binding free energy by nine methods, the binding affinity of camostat, gabexate, and nafamostat to TMPRSS2 showed great advantages compared with bromhexine, where the nafamostat was surprisingly found to present two reasonable binding conformations (forward and reverse directions).	nafamostat	120-130	transmembrane serine protease 2	Homo sapiens	134-141
34787160-6	2021	Through the results of calculating binding free energy by nine methods, the binding affinity of camostat, gabexate, and nafamostat to TMPRSS2 showed great advantages compared with bromhexine, where the nafamostat was surprisingly found to present two reasonable binding conformations (forward and reverse directions).	nafamostat	202-212	transmembrane serine protease 2	Homo sapiens	134-141
34406864-11	2021	Therefore, this study revealed that, at least, TMPRSS2 is involved in HE cleavage and suggested that nafamostat could be a candidate for therapeutic drugs of ICV infection.	nafamostat	101-111	transmembrane serine protease 2	Homo sapiens	47-54
34406858-4	2021	Similarly, inhibition of TMPRSS2 protease activity by camostat mesylate or nafamostat mesylate prevents infection mediated by the TMPRSS2-dependent and cathepsin-independent pathway.	nafamostat	75-94	transmembrane serine protease 2	Homo sapiens	130-137
34100014-4	2021	Similarly, inhibition of TMPRSS2 protease activity by camostat mesylate or nafamostat mesylate prevents infection mediated by the TMPRSS2-dependent and cathepsin-independent pathway.	nafamostat	75-94	transmembrane serine protease 2	Homo sapiens	25-32
34590967-7	2021	PCA discloses the evidence of the structural similarities to the corresponding complexes of L1, L2, and L6 with the complex of TMPRSS2(TM) and Nafamostat mesylate (TM-NAM).	nafamostat	143-162	transmembrane serine protease 2	Homo sapiens	127-134
34575594-2	2021	Nafamostat mesylate (NFM) suppresses transmembrane serine protease 2 and SARS-CoV-2 S protein-mediated fusion.	nafamostat	0-19	transmembrane serine protease 2	Homo sapiens	37-68
34473771-0	2021	Nafamostat mesilate, a nuclear factor kappa B inhibitor, enhances the antitumor action of radiotherapy on gallbladder cancer cells.	nafamostat	0-19	nuclear factor kappa B subunit 1	Homo sapiens	23-45
34473771-2	2021	The synthetic protease inhibitor nafamostat mesilate (NM) inhibits NF-kappaB activity and exerts antitumor actions in various types of cancer.	nafamostat	33-52	nuclear factor kappa B subunit 1	Homo sapiens	67-76
34473771-2	2021	The synthetic protease inhibitor nafamostat mesilate (NM) inhibits NF-kappaB activity and exerts antitumor actions in various types of cancer.	nafamostat	54-56	nuclear factor kappa B subunit 1	Homo sapiens	67-76
34473771-7	2021	In vitro, NM inhibited radiation-induced NF-kappaB activity.	nafamostat	10-12	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	41-50
34473771-11	2021	Overall, NM enhanced the antitumor action of radiotherapy on GBC cells by suppressing radiation-induced NF-kappaB activity.	nafamostat	9-11	nuclear factor kappa B subunit 1	Homo sapiens	104-113
34340553-0	2021	The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.	nafamostat	22-32	transmembrane serine protease 2	Homo sapiens	4-11
34340553-8	2021	In mice sensitized to SARS-CoV-2 infection by transduction with human ACE2, intranasal nafamostat treatment prior to or shortly after SARS-CoV-2 infection significantly reduced weight loss and lung tissue titers.	nafamostat	87-97	angiotensin converting enzyme 2	Homo sapiens	70-74
34340553-9	2021	Similarly, prophylactic intranasal treatment with nafamostat reduced weight loss, viral burden, and mortality in K18-hACE2 transgenic mice.	nafamostat	50-60	angiotensin converting enzyme 2	Homo sapiens	117-122
34100014-4	2021	Similarly, inhibition of TMPRSS2 protease activity by camostat mesylate or nafamostat mesylate prevents infection mediated by the TMPRSS2-dependent and cathepsin-independent pathway.	nafamostat	75-94	transmembrane serine protease 2	Homo sapiens	130-137
34209110-6	2021	These results suggest that the proposed compounds, in addition to Camostat and Nafamostat, could be effective TMPRSS2 inhibitors for COVID-19 treatment by occupying the S1 pocket with the hallmark positively charged groups.	nafamostat	79-89	transmembrane serine protease 2	Homo sapiens	110-117
35535951-5	2022	Keeping this target as the goal of the paper, the potential repurposing drugs, Nafamostat, Camostat, Silmitasertib, Valproic acid, and Zotatifin with host-proteins HDAC2, CSK22, eIF4E2 are studied to elucidate energetics, kinetics, and dissociation pathways.	nafamostat	79-89	histone deacetylase 2	Homo sapiens	164-169
34130375-9	2021	The best hit compounds on the human ACE2 were the lopinavir (-10.1 kcal/mol), ritonavir (-8.9 kcal/mol), and nafamostat (-8.7 kcal/mol).	nafamostat	109-119	angiotensin converting enzyme 2	Homo sapiens	36-40
34130375-11	2021	Nafamostat showed a dual bridging potential against ACE2 and spike glycoprotein, and could therefore be a promising lead compound in the prevention and control of this disease.	nafamostat	0-10	angiotensin converting enzyme 2	Homo sapiens	52-56
34541574-2	2021	Here, we evaluate nafamostat mesylate, a potent broad-spectrum serine protease inhibitor that blocks host protease activation of the viral spike protein.	nafamostat	18-37	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	139-144
34130375-3	2021	Thus, in this current computational study we carried out molecular docking experiments to assess the bridging potentials of some commercial drugs such as chloroquine, hydroxychloroquine, lopinavir, ritonavir, nafamostat, camostat, famotidine, umifenovir, nitazoxanide, ivermectin, and fluvoxamine at the interface between human ACE2 and the coronavirus spike glycoprotein complex.	nafamostat	209-219	angiotensin converting enzyme 2	Homo sapiens	328-332
34075338-0	2021	Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach.	nafamostat	110-120	transmembrane serine protease 2	Homo sapiens	48-55
34075338-5	2021	Hence, we have used a molecular dynamics (MD) simulated homology model of TMPRSS2 to study the inhibition mechanism of experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride (BHH) using molecular modeling techniques.	nafamostat	170-180	transmembrane serine protease 2	Homo sapiens	74-81
34075338-7	2021	Molecular docking analysis revealed that Camostat mesylate and its structural analogue Nafamostat interact strongly with residues His296 and Ser441 present in the catalytic triad of TMPRSS2, whereas BHH binds with Ala386 along with other residues.	nafamostat	87-97	transmembrane serine protease 2	Homo sapiens	182-189
35535951-5	2022	Keeping this target as the goal of the paper, the potential repurposing drugs, Nafamostat, Camostat, Silmitasertib, Valproic acid, and Zotatifin with host-proteins HDAC2, CSK22, eIF4E2 are studied to elucidate energetics, kinetics, and dissociation pathways.	nafamostat	79-89	eukaryotic translation initiation factor 4E family member 2	Homo sapiens	178-184
35072549-5	2022	Two known TMPRSS2 inhibitors, namely camostat and nafamostat, approved drugs for the treatment of pancreatitis, are under clinical trials as potential drugs against COVID-19.	nafamostat	50-60	transmembrane serine protease 2	Homo sapiens	10-17
35167033-0	2022	Identification of nafamostat mesylate as a selective stimulator of NK cell IFN-gamma production via metabolism-related compound library screening.	nafamostat	18-37	interferon gamma	Homo sapiens	75-84
35348901-2	2022	Nafamostat mesilate (NM), a synthetic serine protease, is used widely for CKRT anticoagulation in Japan and Korea.	nafamostat	0-19	coagulation factor II, thrombin	Homo sapiens	38-53
35348901-2	2022	Nafamostat mesilate (NM), a synthetic serine protease, is used widely for CKRT anticoagulation in Japan and Korea.	nafamostat	21-23	coagulation factor II, thrombin	Homo sapiens	38-53
35294338-7	2022	The mechanism of the protease inhibitors nafamostat and camostat may extend beyond inhibition of TMPRSS2 to coagulation-induced spike cleavage.	nafamostat	41-51	transmembrane serine protease 2	Homo sapiens	97-104
35294338-7	2022	The mechanism of the protease inhibitors nafamostat and camostat may extend beyond inhibition of TMPRSS2 to coagulation-induced spike cleavage.	nafamostat	41-51	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	128-133
35215982-2	2022	Nafamostat, a potent TMPRSS2 inhibitor as well as a candidate for anti-SARS-CoV-2 drug, possesses the same acyl substructure as camostat, but is known to have a greater antiviral effect.	nafamostat	0-10	transmembrane serine protease 2	Homo sapiens	21-28
35215982-3	2022	A unique aspect of the molecular binding of nafamostat has been recently reported to be the formation of a covalent bond between its acyl substructure and Ser441 in TMPRSS2.	nafamostat	44-54	transmembrane serine protease 2	Homo sapiens	165-172
35215982-5	2022	In silico analysis showed that Asp435 significantly contributes to the binding of nafamostat and camostat to TMPRSS2, while Glu299 interacts strongly only with nafamostat.	nafamostat	82-92	transmembrane serine protease 2	Homo sapiens	109-116
35215982-6	2022	The estimated binding affinity for each compound with TMPRSS2 was actually consistent with the higher activity of nafamostat; however, the evaluation of the newly synthesized nafamostat derivatives revealed that the predicted binding affinity did not correlate with their anti-SARS-CoV-2 activity measured by the cytopathic effect (CPE) inhibition assay.	nafamostat	114-124	transmembrane serine protease 2	Homo sapiens	54-61
35215982-8	2022	These results strongly indicate that the ease of covalent bond formation with Ser441 in TMPRSS2 possibly plays a major role in the anti-SARS-CoV-2 effect of nafamostat and its derivatives.	nafamostat	157-167	transmembrane serine protease 2	Homo sapiens	88-95
35063125-6	2022	Moreover, entry of SARS-CoV-2 into BCECs could be reduced by anti-spike-, anti-angiotensin-converting enzyme 2 (ACE2)-, and anti-neuropilin-1 (NRP1)-specific antibodies or the transmembrane protease serine subtype 2 (TMPRSS2) inhibitor nafamostat.	nafamostat	236-246	neuropilin 1	Homo sapiens	129-141
35063125-6	2022	Moreover, entry of SARS-CoV-2 into BCECs could be reduced by anti-spike-, anti-angiotensin-converting enzyme 2 (ACE2)-, and anti-neuropilin-1 (NRP1)-specific antibodies or the transmembrane protease serine subtype 2 (TMPRSS2) inhibitor nafamostat.	nafamostat	236-246	neuropilin 1	Homo sapiens	143-147
35063125-6	2022	Moreover, entry of SARS-CoV-2 into BCECs could be reduced by anti-spike-, anti-angiotensin-converting enzyme 2 (ACE2)-, and anti-neuropilin-1 (NRP1)-specific antibodies or the transmembrane protease serine subtype 2 (TMPRSS2) inhibitor nafamostat.	nafamostat	236-246	transmembrane serine protease 2	Homo sapiens	217-224
34991643-0	2022	Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness.	nafamostat	0-10	toll-like receptor 7	Mus musculus	44-48
34991643-9	2022	Exogenous administration of nafamostat suppressed the hepatic inflammatory response, significantly reducing TNF and IFN-gamma expression, but had no effect on lung or brain cytokine production.	nafamostat	28-38	tumor necrosis factor	Mus musculus	108-111
34991643-12	2022	In turn, we show that nafamostat has a systemic anti-inflammatory effect in the presence of the TLR7/8 agonist.	nafamostat	22-32	toll-like receptor 7	Mus musculus	96-102
34991643-9	2022	Exogenous administration of nafamostat suppressed the hepatic inflammatory response, significantly reducing TNF and IFN-gamma expression, but had no effect on lung or brain cytokine production.	nafamostat	28-38	interferon gamma	Mus musculus	116-125
34991643-13	2022	Therefore, the results indicate that nafamostat has anti-inflammatory actions, beyond its ability to inhibit TMPRSS2, that might potentiate its anti-viral actions in pathologies such as COVID-19.	nafamostat	37-47	transmembrane protease, serine 2	Mus musculus	109-116